1. FRI0003 Determination of interferon (IFN) signatures for sle patients may be critical for optimal treatment selection but depends on the genes chosen: report from the bold (biomarkers of lupus disease) study. (23rd January 2014) Authors: Hill, A. A.; Immermann, F. W.; Zhang, Y.; Reddy, P. S.; Zhou, T.; O'Toole, M.; Whitley, M. Z.; Masferrer, J.; Wu, P. W.; Paradis, T.; Sridharan, S.; Merrill, J. T.; James, J. A. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0382 Impact of Treatments on Major Immunologic Pathways in SLE Depends on Type I Interferon Signature: Analysis from Biomarkers of Lupus Disease (BOLD) Study. (10th June 2014) Authors: Merrill, J.T.; Immermann, F.W.; Zhou, T.; O'Toole, M.; Whitley, M.; Hill, A.A.; Zhang, Y.; von Schack, D.; Reddy, P.S.; Masferrer, J.L.; Kamp, S.; Guthridge, J.M.; Thanou, A.; Wu, P.; Paradis, T.; Mounts, W.M.; James, J.A.; Sridharan, S.T. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗